Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 31 n° 321

Posts Tagged ‘conference’

GigCapital2, Inc. to Attend the UBS Global Technology Conference

Posted by fidest press agency su giovedì, 21 novembre 2019

New York Hilton Midtown – New York City Monday – Wednesday, December 9-11, 2019 8:30 a.m. – 4:30 p.m. Eastern Time UBS Global TMT Conference. GigCapital Group (“GigCapital”) is a Private-to-Public Equity (PPE) technology, media, and telecommunications (TMT) focused investment group led by an affiliated team of technology industry corporate executives and entrepreneurs, and TMT operational and strategic experts in the private and public markets, including substantial, success-proven M&A and IPO activities. The group deploys a unique Mentor-InvestorsTM methodology to partner with exceptional TMT companies, managed by dedicated and experienced entrepreneurs. The GigCapital Private-to-Public Equity (PPE) companies (also known as blank check companies or Special Purpose Acquisition Companies (SPACs)) offer financial, operational and executive mentoring to U.S. and overseas private, and non-U.S. public companies, in order to accelerate their path from inception and as a privately-held entity into the growth-stage as a publicly traded company in the U.S. The partnership of GigCapital with these companies continues through an organic and roll-up strategy growth post the transition to a public company. GigCapital was launched in 2017 with the vision of becoming the lead franchise in incepting and developing TMT Private-to-Public Equity (PPE) companies. For more information, visit http://www.gigcapitalglobal.com.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Stibo Systems to Host MDM Conference in Melbourne

Posted by fidest press agency su giovedì, 21 novembre 2019

Stibo Systems, the only master data management (MDM) company focused on putting Your business first has announced its Master Data Management Conference in Melbourne, Australia, on November 28th at the Treetops Venue, Melbourne Museum.
The conference provides a forum for business leaders across all industries to be at the nexus of ideas and policies that will impact the MDM marketplace. Attendees will explore critical topics such as industry data challenges, change enablement and readiness, customer centric design and protecting customer privacy.“Today, mobile, AI, the cloud, big data, blockchain, robotics and virtual reality are just a few of the rapidly-evolving technologies companies everywhere are being required to understand and master,” says Manfred Heckt, Managing Director, Stibo Systems Pty. Ltd. “Our keynote will explore this topic, and how business leaders need to transform their own skills in order to survive and thrive in this new digital world.” Speakers at the event include: Keynote speaker, Stephen Scheeler, ‘The Digital CEO’; Neil Cresswell, Chief Information Officer, NXP; David Littlewood, Head of Information and Analytics, GPC/Repco; Jonathan Moeller, Founder, foryouandyourcustomers and Stefan Conrad, Merchandise Process and Support Manager, Officeworks.
The one-day event also features a full slate of Stibo Systems’ leadership, discussing recent developments in our Digital Business Hub strategy, the company’s plans for continued growth and innovation across the seamlessly integrated suite of multidomain MDM solutions, as well as continued innovations in cloud, machine learning and artificial intelligence.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

Conference on multilateral diplomacy and future warfare

Posted by fidest press agency su mercoledì, 20 novembre 2019

Rome 22.11.2019—23.11.2019 International Humanitarian Law Via Liguria 20 Conference on multilateral diplomacy and future warfare
To commemorate the 70th anniversary of the 1949 Geneva Conventions, the Istituto Svizzero and the Swiss Embassy in Italy invite, in collaboration with the University Roma Tre and The University of Geneva, the Roman public to a discussion about both the achievements and the challenges in current international humanitarian law (IHL). The DISPUTE series provides a platform for citizen engagement relating to the globalization and the future of contemporary societies. Proposing a new topic every year, the forum aims to strengthen civic participation and public debate.This year’s edition puts the role and relevance of the IHL up for debate. Featuring politicians, scholars, representatives of states, armed forces, the Red Cross Movement and non-governmental activist groups, interested citizens have the chance to participate in an informed discussion with experienced specialists who can give a clear idea of what IHL is, what it does, and what its challenges for the future are. The conference will be accompanied by two commentators (already confirmed is Yves Daccord, general director, ICRC) whose role is to highlight important themes and arguments in wrap-up sessions following each panel.The conference will focus on three different fields of interest:
Multilateral diplomacy and IHL: does it still work? During the last decades, multilateral diplomacy has not always been effective despite sustained efforts of the international community to develop new international instruments in order to face current and upcoming challenges in IHL. The trend in favor of unilateral solutions and the shifting of priority from international concerns to national interests is noticeable in a number of States.Inherent features of IHL render law-making in this domain particularly difficult. For instance, various actors are involved in contemporary armed conflicts, such as organized armed groups or international organizations and accommodating their perspectives in a State-centric international system remains a challenge.Against this backdrop, the DISPUTE series will offer the opportunity to panelists and the audience to reflect on possible venues to enhance and continuously ensure effective protection to victims of armed conflicts. Furthermore, the session will explore the continued relevance of the Geneva Conventions and other multilateral IHL treaties highlighting best practice examples from armed conflict situations.Two panels will focus on selected challenges that have arisen in recent armed conflicts. Particular attention will be paid to non-international armed conflicts and related issues pertaining to non-state actors as well as to the protection of cultural heritage in armed conflicts. Discussions will not only demonstrate the complexity of IHL application and humanitarian action in armed conflicts but also give a picture of the global community’s handling of these complexities.
The third session concerns new technologies and their potential impact on the future of warfare. The rapid development of technologies and artificial intelligence with potential military applications may radically change the face of armed conflicts. Drones are increasingly used, cyberspace has emerged as a new battlefield, and automated weapons systems such as combat robots may be defining future wars. At the same time, modern technologies can improve the application of IHL and the enforcement of such rules in case of violations. These changes have not only ethical implications but also pose legal and practical problems to IHL. A simultaneous translation in English-Italian will be provided.

Posted in Estero/world news, Roma/about Rome | Contrassegnato da tag: , , , | Leave a Comment »

The AACR Tumor Immunology and Immunotherapy Conference

Posted by fidest press agency su mercoledì, 20 novembre 2019

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will participate in the AACR Tumor Immunology and Immunotherapy conference at the Boston Marriott Copley Place in Boston, MA, November 17-20, including poster presentations on November 18th and 19th. The company will showcase ImmunoID NeXT™, the first platform to enable comprehensive analysis of both a tumor and its immune microenvironment from a single sample. ImmunoID NeXT™ can be used to investigate the key tumor- and immune-related areas of cancer biology, consolidating multiple oncology biomarker assays into one and maximizing the biological information that can be generated from a precious tumor specimen.
Personalis, Inc. is a growing cancer genomics company transforming the development of next-generation therapies by providing more comprehensive molecular data about each patient’s cancer and immune response. The company’s NeXT™ Platform is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample. Personalis also provides genomic information to the VA Million Veterans Program as part of their goal to sequence over a million veteran genomes.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

Global Executive Education Conference

Posted by fidest press agency su lunedì, 18 novembre 2019

Santa Clara University’s Silicon Valley Executive Center Nov. 20 to 22, 2019.The conference, which will gather 200 executive-ed professionals from 71 universities across 20 countries, will be held on the campus of Santa Clara University.Attendees are university professionals from around the world who pinpoint the most pressing executive-educational needs among corporate leaders, and offer certifications or other educational programming to keep their workforce at the forefront of business innovation.The event’s theme this year is “Leading Executive Education in a Changing World.” It is focused on sourcing the cutting-edge executive education that business leaders will need in the years ahead to address dramatic changing work-force dynamics in the global economy, said Dennis Lanham, executive director of SCU’s Silicon Valley Executive Center.The first keynote speaker will be New York Times best-selling author Patrick Lencioni, who will give a speech that will set the stage for the first of two workshops. The topic—how to create healthy teams and organizations—will focus on making team-member development a top priority within executive-education organizations at universities.In addition, Nancy Hauge, chief human resources officer of Automation Anywhere—a San Jose-based company that caters to enterprises looking to deploy a digital workforce of software bots that complete business processes end-to-end—will cover the challenges and opportunities from automation occurring across numerous industries. Leadership author and Dean’s Executive Fellow of Leadership at SCU, Jim Kouzes, will give a third keynote on his Learning Leadership model based on his best-selling book, The Leadership Challenge, co-authored by SCU faculty member Barry Posner.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

New Industrial Imaging Products at ASNT Fall 2019 Conference & Exhibit

Posted by fidest press agency su lunedì, 18 novembre 2019

Varex Imaging Corporation (Nasdaq: VREX) will exhibit its latest industrial Nondestructive Testing (NDT) imaging products at the Annual Meeting for the American Society for Nondestructive Testing in Las Vegas from November 18-21, 2019. ASNT Fall is a global event to share ideas and expertise in the field and is attended by many NDT specialists ranging from researchers to leading experts.
At the show, Varex will be introducing their new ‘Varex Industrial’ brand which has been created to cover their expanding Industrial and Security Inspection portfolio. This portfolio includes two recent acquisitions: Direct Conversion (2019), a leading manufacturer of Photon Counting Linear Array Digital Detectors which can be used in industrial, security, and food inspection. This follows the acquisition of VMI (2018) who specialize in digital solutions for NDT applications. “We are launching ‘Varex Industrial’ as a brand to promote our growing industrial and security business and to let our customers know that we are committed to the industrial marketplace. To date we have been primarily known as a supplier of medical components. ‘Varex Industrial’ offers NDT and Security customers access to our products as well as our expertise and services,” commented Carl LaCasce, Senior Vice President and General Manager of Industrial Imaging for Varex Imaging Corporation. A team of engineers and experts will be on hand to at ASNT Fall to guide you through the services Varex offers as well as their X-ray tubes and linear accelerators, digital detectors and other image processing solutions. These components are designed for industrial imaging systems used in electronics inspection, casting and weld/pipeline inspection, metrology, industrial cone beam computed tomography, materials science and in-line quality control for automotive, aerospace and electronics manufacturing.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

Stifel 2019 Healthcare Conference

Posted by fidest press agency su lunedì, 18 novembre 2019

Blade Therapeutics, a biopharmaceutical company advancing novel anti-fibrotic therapies, today announced that Wendye Robbins, M.D., President and Chief Executive Officer, will present at the Stifel 2019 Healthcare Conference on Tuesday, November 19, 2019 at 1:50 p.m. Eastern Time.Blade Therapeutics is a private, clinical-stage biopharmaceutical company advancing novel anti-fibrotic therapies to meet important patient needs. Blade’s lead compound, BLD-2660, is a highly selective calpain inhibitor targeted for the treatment of chronic fibrotic diseases. BLD-2660 recently completed a Phase I, healthy volunteer, dose escalation study in Australia. The Company plans to submit a CTN application to initiate a Phase II trial in patients with idiopathic pulmonary fibrosis in early 2020. Blade’s second candidate, BLD-0409, is a Phase I ready autotaxin inhibitor for the treatment of multiple fibrotic diseases. The Company plans to initiate a Phase 1 study for BLD-0409 in 1Q 2020. Blade has assembled a critical mass of anti-fibrotic drug development expertise within its top-tier leadership team and a world-class network of advisors. Lead investors in Blade include MPM Capital, Deerfield, Pfizer Ventures, One Ventures, Osage Partners, Bristol-Myers Squibb and Novartis Institute of Biomedical Research. Please visit http://www.blademed.com/ for more information.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Early Stage Lung Cancer at Innovation Summit San Francisco Conference

Posted by fidest press agency su domenica, 17 novembre 2019

Navigation Sciences™ will provide an update at the annual Medtech Strategist Innovation Summit San Francisco 2019 Conference on its Image Guided, Video Assisted Surgery (iVATS™) technology for the minimally invasive identification and removal of early stage lung cancer, the company announced today. The conference will take place in Burlingame, California on November 19, 2019.
The emergence of CT chest scanning as an effective tool in high risk populations to detect lung cancer at an early stage and lower cancer deaths is creating new opportunities to improve lung surgery. Removal of small tumors deep inside the lung with appropriate margins remains a significant challenge, as insufficient distance between the tumor and resection margin is associated with recurrence and death. Current surgical approaches either remove excess tissue via lobectomy, which lowers recurrence risk but results in more impaired lung function, or smaller, wedge resections, which reduces lung impairment but may increase recurrence risk.The Navigation Sciences™ solution integrates with multi-modal (imaging and surgery) technology and includes an active, GPS enabled marker (fiducial), proprietary, real-time navigation algorithms, and tumor cutting devices that allow for surgical precision specific to the patient’s anatomy. Radiology images are synchronized with real-time information to enable the clinician to perform surgery with precision guidance. The technology’s proof-of-concept was demonstrated in a Phase I-II clinical trial published in the Journal of Surgical Oncology. In the study, involving 25 patients (23 with early stage lung cancer), there were no significant complications, all nodules were fully resected with negative margins, and the technology was shown to integrate with surgical workflow.There are an estimated 87,000 patients in the U.S. diagnosed each year with early stage lung cancer and that number is expected to grow with growing recognition of CT X-ray screening’s value in early detection and favorable reimbursement coverage. Beyond lung cancer, the technology has significant potential in other soft tissue cancer surgeries including breast cancer, where an estimated 250,000 lumpectomies are performed annually, as well as liver, thyroid and brain tumors.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

Impinj to Participate in Upcoming Investor Conference

Posted by fidest press agency su sabato, 16 novembre 2019

New York, NY Tuesday, November 19, 2019 at 8:35 a.m. ET 2019 RBC Global Technology, Internet, Media and Telecommunications Conference Impinj, Inc. (NASDAQ: PI), a leading provider and pioneer of RAIN RFID solutions for identifying, locating and authenticating everyday items, today announced Chris Diorio, co-founder and CEO, will participate in a fireside chat at the investor conference. mpinj, Inc. (NASDAQ: PI) wirelessly connects billions of everyday items such as apparel, medical supplies, automobile parts, luggage and food to consumer and business applications such as inventory management, patient safety, asset tracking and item authentication. The Impinj platform uses RAIN RFID to deliver timely information about these items to the digital world, thereby enabling the Internet of Things. Impinj is a registered trademark of Impinj, Inc. All other trademarks are the property of their owners.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

Savara to Present at the Stifel 2019 Healthcare Conference

Posted by fidest press agency su sabato, 16 novembre 2019

Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, will be presenting at the Stifel 2019 Healthcare Conference on Tuesday, November 19, 2019 at 3:00 PM ET / 12:00 PM PT at the Lotte New York Palace Hotel. Rob Neville, Savara’s Chief Executive Officer, will represent the Company at the conference. Interested parties can access a live audio webcast on the Investors page of the Savara website at http://www.savarapharma.com/investors/events-presentations/. Archived presentations will be available on Savara’s website for 90 days following the events.Savara is an orphan lung disease company. Savara’s pipeline comprises Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP), in Phase 2a development for nontuberculous mycobacterial (NTM) lung infection in both non-cystic fibrosis (CF) and CF-affected individuals with chronic NTM lung infection; and AeroVanc, a Phase 3-stage inhaled vancomycin for treatment of persistent methicillin-resistant Staphylococcus aureus (MRSA) lung infection in CF. Savara’s strategy involves expanding its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. Savara’s management team has significant experience in orphan drug development and pulmonary medicine, identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approvals and commercialization.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

31st Annual Healthcare Conference

Posted by fidest press agency su venerdì, 15 novembre 2019

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that the company will be participating in the upcoming Piper Jaffray 31st Annual Healthcare Conference in New York City. AtriCure’s management is scheduled to present on Thursday, December 5, 2019, at 12:30 p.m. Eastern Time. Interested parties may access a live audio webcast of the presentation by visiting the “Investors” section of the company’s website at https://ir.atricure.com.
AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure’s Isolator® Synergy™ Ablation System is the first and only medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Cirrus Logic CEO Jason Rhode to Present at NASDAQ Conference

Posted by fidest press agency su giovedì, 14 novembre 2019

London. Cirrus Logic, Inc. (Nasdaq: CRUS) today announced that Jason Rhode, president and chief executive officer, will present at the NASDAQ 41st Investor Conference at The May Fair Hotel in London at 9:45 a.m. GMT on Tuesday, Dec. 3, 2019. A live webcast of the presentation will be available on the company’s investor relations website. An archived replay of the webcasts will be available on the website following the events. Cirrus Logic is a leader in high-performance, low-power ICs for audio, voice and other signal-processing applications. Cirrus Logic’s products span the entire audio signal chain, from capture to playback, providing innovative products for the world’s top smartphones, tablets, digital headsets, wearables and emerging smart home applications. With headquarters in Austin, Texas, Cirrus Logic is recognized globally for its award-winning corporate culture. Check us out at http://www.cirrus.com.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

ICTSTEM 2020: International Conference on Technologies in STEM

Posted by fidest press agency su giovedì, 14 novembre 2019

Singapore on 9-10th July 2020. The conference aims to further the application of technology education within STEM and specific learning areas. Within Technology education, students use design and/or computational thinking and technologies to generate and produce designed solutions both digital and physical for authentic problems. As such it applies many of the areas of STEM.We invite practitioners and researchers to network and share their experiences. Teachers, and heads of learning areas as well as teacher educators, researchers and HDR researchers from K to higher education are all encouraged to attend.A broad range of technology education topics, including significant developments as well as innovative uses of technology that promote learning, performance, and instruction, will be presented at ICTSTEM 2020. Join us for this exciting Academic Conference in Singapore from 9th to 10th July 2020 at the Furama Riverfront Hotel.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

The Marcus Corporation to Participate at the Southwest IDEAS Investor Conference

Posted by fidest press agency su giovedì, 14 novembre 2019

Dallas on Wednesday, November 20, 2019 at 8:55 a.m. Eastern Time/7:55 a.m. Central Time.Interested parties can listen to a live audio webcast of the presentation by accessing the investor relations section of the company’s website: http://www.marcuscorp.com, or directly at: http://www.wsw.com/webcast/threepa30/mcs. Listeners should go to the website at least 15 minutes prior to the start of the presentation to download and install any necessary audio software. A replay of the presentation will be archived on the company’s website for 90 days after the conclusion of the live event.The mission of the IDEAS Conferences is to provide independent regional venues for quality companies to present their investment merits to an influential audience of investment professionals. The conferences are held annually in Boston, Chicago and Dallas and are produced by Three Part Advisors, LLC.
Headquartered in Milwaukee, The Marcus Corporation is a leader in the lodging and entertainment industries, with significant company-owned real estate assets. The Marcus Corporation’s theatre division, Marcus Theatres®, is the fourth largest theatre circuit in the U.S. and currently owns or operates 1,106 screens at 91 locations in 17 states under the Marcus Theatres, Movie Tavern® by Marcus and BistroPlexSM brands. The company’s lodging division, Marcus® Hotels & Resorts, owns and/or manages 20 hotels, resorts and other properties in eight states. For more information, please visit the company’s website at http://www.marcuscorp.com.

Posted in Estero/world news | Contrassegnato da tag: , , , | Leave a Comment »

Millendo Therapeutics to Present at the Stifel 2019 Healthcare Conference

Posted by fidest press agency su giovedì, 14 novembre 2019

Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company developing novel treatments primarily for orphan endocrine diseases, announced today that Julia C. Owens, Ph.D., President and Chief Executive Officer, will present at the Stifel 2019 Healthcare Conference in New York City on Tuesday, November 19, 2019 at 9:45 a.m. EST.A live webcast of the presentation will be available on the Investors & Media section of Millendo’s website at http://investors.millendo.com. A replay of the webcast will be archived on Millendo’s website for 30 days following the presentation.Millendo Therapeutics is a late-stage biopharmaceutical company primarily focused on developing novel treatments for orphan endocrine diseases where current therapies do not exist or are insufficient. As a leading orphan endocrine company, Millendo creates distinct and transformative treatments where there is a significant unmet medical need. The company is currently advancing livoletide for the treatment of Prader-Willi syndrome, nevanimibe for the treatment of classic congenital adrenal hyperplasia and MLE-301 for the treatment of vasomotor symptoms associated with menopause. For more information, please visit http://www.millendo.com.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Oncternal Therapeutics to Present at Stifel Healthcare Conference

Posted by fidest press agency su giovedì, 14 novembre 2019

Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that James Breitmeyer, M.D., Ph.D., President and Chief Executive Officer, will present a company overview at the Stifel 2019 Healthcare Conference in New York City on Tuesday, November 19, 2019 at 10:20 a.m. ET / 7:20 a.m. PT.A live webcast of the presentation will be available online via a link from the investor relations page of the Company’s website at http://www.oncternal.com, and the webcast will be archived there for at least 30 days following the event.
Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer generation or progression. The pipeline includes cirmtuzumab, an investigational monoclonal antibody designed to inhibit the ROR1 pathway, a type I tyrosine kinase-like orphan receptor, that is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), and TK216, an investigational small-molecule compound that is designed to inhibit E26 transformation specific (ETS) family oncoproteins, that is being evaluated in a Phase 1 clinical trial for patients with Ewing sarcoma alone and in combination with vincristine chemotherapy. In addition, Oncternal has a program to develop a CAR-T therapy that targets ROR1, which is currently in preclinical development as a potential treatment for hematologic cancers and solid tumors. More information is available at http://www.oncternal.com.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Conference on multilateral diplomacy and future warfare

Posted by fidest press agency su mercoledì, 13 novembre 2019

Rome november 22-23 H15:00 Istituto Svizzero Villa Maraini Via Ludovisi 48 To commemorate the 70th anniversary of the 1949 Geneva Conventions, the Istituto Svizzero and the Swiss Embassy in Italy invite, in collaboration with the University Roma Tre and The University of Geneva, the Roman public to a discussion about both the achievements and the challenges in current international humanitarian law (IHL). The DISPUTE series provides a platform for citizen engagement relating to the globalization and the future of contemporary societies. Proposing a new topic every year, the forum aims to strengthen civic participation and public debate.
This year’s edition puts the role and relevance of the IHL up for debate. Featuring politicians, scholars, representatives of states, armed forces, the Red Cross Movement and non-governmental activist groups, interested citizens have the chance to participate in an informed discussion with experienced specialists who can give a clear idea of what IHL is, what it does, and what its challenges for the future are. The conference will be accompanied by two commentators (already confirmed is Yves Daccord, general director, ICRC) whose role is to highlight important themes and arguments in wrap-up sessions following each panel.The conference will focus on three different fields of interest:Multilateral diplomacy and IHL: does it still work? During the last decades, multilateral diplomacy has not always been effective despite sustained efforts of the international community to develop new international instruments in order to face current and upcoming challenges in IHL. The trend in favor of unilateral solutions and the shifting of priority from international concerns to national interests is noticeable in a number of States.Inherent features of IHL render law-making in this domain particularly difficult. For instance, various actors are involved in contemporary armed conflicts, such as organized armed groups or international organizations and accommodating their perspectives in a State-centric international system remains a challenge.Against this backdrop, the DISPUTE series will offer the opportunity to panelists and the audience to reflect on possible venues to enhance and continuously ensure effective protection to victims of armed conflicts. Furthermore, the session will explore the continued relevance of the Geneva Conventions and other multilateral IHL treaties highlighting best practice examples from armed conflict situations.
Lights and shadows: how is IHL interpreted and applied?Two panels will focus on selected challenges that have arisen in recent armed conflicts. Particular attention will be paid to non-international armed conflicts and related issues pertaining to non-state actors as well as to the protection of cultural heritage in armed conflicts. Discussions will not only demonstrate the complexity of IHL application and humanitarian action in armed conflicts but also give a picture of the global community’s handling of these complexities.
The future of warfare: what set of rules do we need?The third session concerns new technologies and their potential impact on the future of warfare. The rapid development of technologies and artificial intelligence with potential military applications may radically change the face of armed conflicts. Drones are increasingly used, cyberspace has emerged as a new battlefield, and automated weapons systems such as combat robots may be defining future wars. At the same time, modern technologies can improve the application of IHL and the enforcement of such rules in case of violations. These changes have not only ethical implications but also pose legal and practical problems to IHL.The conference is free and is only upon registration. To sign up please send an email to prenotazioni@istitutosvizzero.it. A simultaneous translation in English-Italian will be provided.
H15:30 Multilateral Diplomacy (moderated by Gloria Gaggioli, University of Geneva) Fausto Pocar (Sanremo Institute), Academic Perspective, Valentin Zellweger (Ambassador, Permanent Representative of Switzerland to the UN), State Perspective
Steven Hill (Legal Adviser NATO), IO Perspective, Els Debuf (Deputy Head for Europe ICRC), ICRC Perspective, Noam Lubell (University of Essex), Developing New Guidelines for Investigating IHL Violations. H16:20 Moderated round-table discussion with panelists and Q&A for audience
H17:45 Best Practice in IHL Giulio Bartolini (Roma Tre), The Continued Relevance of the Geneva Conventions and other Multilateral IHL Treaties: Success Stories and the Application of IHL
H18:00 Wrap-up sessio
23.11.2019 – Day 2 H11:00 Non-State Actors (moderated by Emanuela-Chiara Gillard, University of Oxford)
Marco Sassoli, University of Geneva, The Law of Non-International Armed Conflicts Luisa Vierucci (University of Florence), Agreements regulating a non-international armed conflict: what impact on IHL? Sandra Krähenmann (Geneva Call), Engaging with Non-State-Actors H11:30 Moderated round-table discussion with panelists and Q&A for audience H12:30 Wrap-up session
H14:30 Cultural Heritage (moderated by Kristin Hausler, British Institute of International and Comparative Law) Roger O’Keefe (University Bocconi) Cultural Heritage and International Humanitarian Law: From Atrocity to Capacity Fabrizio Parulli (Carabinieri), The Blue Helmets for Culture Initiative Aparna Tandon (ICCROM), First Aid and Resilience for Cultural Heritage
H15:00 Moderated round-table discussion with panelists and Q&A for audience H16:00 Wrap-up session
H17:00 Future Warfare (moderated by Jean-Marc Rickli, GCSP) Marco Roscini (University of Westminster), Cyberwarfare Kaja Ciglic (Microsoft), The Role of New Technologies in Armed Conflicts, Neha Jain (European University Institute), Accountability for violations of international humanitarian law
H17:30 Moderated round-table discussion with panelists and Q&A for audience
H18:30 Wrap-up session
H19:00 Final debate

Posted in Estero/world news, Roma/about Rome | Contrassegnato da tag: , , | Leave a Comment »

31st Annual Piper Jaffray Healthcare Conference

Posted by fidest press agency su lunedì, 11 novembre 2019

Aruna Bio, Inc., a leader in the development of neural exosomes for the treatment of neurodegenerative diseases, today announced that Dr. Mark Sirgo, Chief Executive Officer, and Dr. Steve Stice, Chief Scientific Officer, will be presenting at the 31st Annual Piper Jaffray Healthcare Conference in New York City on Thursday, December 5th at 8:10 AM Eastern time.Drs. Sirgo and Stice will discuss the utilization of neural exosomes as both a therapeutic and a delivery vehicle to treat neurodegenerative diseases and stroke. The presentation will include data on Aruna Bio’s proprietary neural exosome platform, which has demonstrated therapeutic benefit in multiple animal models of stroke and is also being developed for the treatment of amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Dr. Sirgo will also discuss the company’s going forward strategy and key milestones for 2020.
Aruna Bio is harnessing the natural abilities of neural exosomes to cross the blood brain barrier and enhance the body’s anti-inflammatory, self-repair and protective mechanisms to treat a range of neurodegenerative disorders. Aruna Bio is also leveraging its proprietary exosomes and manufacturing platform to create synergistic therapies by enhancing exosomes with RNA, oligonucleotides, antibodies and small molecules. http://www.arunabio.com

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

Stephens 2019 Nashville Investment Conference

Posted by fidest press agency su domenica, 10 novembre 2019

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that the company is scheduled to participate in the Stephens 2019 Nashville Investment Conference in Nashville, Tennessee. The fireside chat is scheduled to take place on Wednesday, November 13, 2019 at 3:30 p.m. Eastern Time. Matt Korenberg, CFO will attend for Ligand. Ligand is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Our business model creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified and lower-risk business than a typical biotech company. Our business model is based on doing what we do best: drug discovery, early-stage drug development, product reformulation and partnering. We partner with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) to ultimately generate our revenue. Ligand’s Captisol® platform technology is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. OmniAb® is a patent-protected transgenic animal platform used in the discovery of fully human mono-and bispecific therapeutic antibodies. Ligand has established multiple alliances, licenses and other business relationships with the world’s leading pharmaceutical companies including Novartis, Amgen, Merck, Pfizer, Celgene, Gilead, Janssen, Baxter International and Eli Lilly.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »

AgilVax to Present at the 2019 NYC Oncology Investor Conference

Posted by fidest press agency su domenica, 10 novembre 2019

Conference on November 12, 2019 at 5:30 PM (ET). The conference is being held at the Perkins Coie law firm, 1155 6th Ave, New York City, NY.AgilVax Inc., announced today that Joseph Patti, PhD, President and Chief Executive Officer, will present an overview of the Company and provide an update on its portfolio of targeted antibody-based therapies addressing multiple cancers at the NYC Oncology Investor.
AgilVax has demonstrated in preclinical in vivo models that antibodies to xCT were able to reduce primary tumor formation and the number of lung metastases. xCT overexpression occurs in several cancers leading to metabolic changes that reprograms cells for growth and progression. AgilVax has multiple solutions to target cancer cells that overexpress xCT and when used in combination with existing therapies or alone have the potential to create a durable response in patients suffering from colorectal and other metastatic cancers.

Posted in Estero/world news | Contrassegnato da tag: , , | Leave a Comment »